Julie Grant co-founded and served as founding CEO of Day One Biopharmaceuticals at Canaan Partners, taking an unusually hands-on operator role for a venture investor by building the company around pediatric oncology and challenging the industry norm of prioritizing adult cancers over children. She functions as an incubator of life science startups within Canaan, founding multiple companies and advancing rapidly from associate to general partner while combining her scientific background with policy influence through roles like her appointment to the National Cancer Advisory Board.

• Strong interest in frontier technology and commercial space infrastructure. Actively celebrates engineering milestones in aerospace, such as successful rocket launches by Astra or Kepler Communications building internet capabilities beyond Earth.
• Deep commitment to pediatric oncology and precision medicine. Frequently champions companies developing treatments for young patients with limited options, most notably highlighting progress and clinical data from Day One Biopharmaceuticals regarding childhood brain cancer.
• Focus on macro-level healthcare venture trends and data. Regularly cites industry reports to track fundraising records and investment activity, often referencing data from Silicon Valley Bank to understand the economic landscape for life sciences.
• Involvement in public policy and high-level patient advocacy. Demonstrates active participation in government initiatives aimed at accelerating medical breakthroughs, such as serving on the board for the Cancer Moonshot initiative to reduce cancer death rates.
• Appreciation for team culture and scientific enthusiasm. Blends professional updates with personal interests, such as coordinating Star Wars costumes with her family and partners or expressing admiration for sailing legends.